Nirsevimab, the first approved preventive treatment against the respiratory syncytial virus that causes bronchiolitis, is said to have prevented 83.21% of hospitalizations in babies under one year of age. This finding is the result of a phase three study carried out on more than 8,000 children in France, Germany and the United Kingdom.
In 2017, healthcare spending directly related to RSV was estimated at €4.82 billion worldwide, Sanofi said.